Related Experiment Videos
[Juvenile dermatomyositis and extensive calcinosis. Treatment with methylprednisolone and methotrexate]
Zoilo Morel Ayala1, Rogelio Martínez Ramírez, Samara Mendieta Zerón
1Departamento de Reumatología. Hospital Infantil de México Federico Gómez. México DF. México.
Abstract:
Juvenile dermatomyositis (JDM) is considered a multisystemic disease of uncertain etiology. The clinical manifestation is a non-suppurative inflammation of the striated muscle, gastrointestinal tract and skin. Dystrophic calcifications are present in 30%-70% of children with JDM. The clinical case we are presenting is a 4 years old female with diagnosis of JDM in accordance to the Bohan and Peters criteria (very early presentation age) with extensive calcinosis, classified as functional class III, without being able to sit down or flex her knees. She was treated with IV methylprednisolone (MPS) bolus every 14 days and oral methotrexate, with improvement of her clinical condition. Even though calcinosis is a frequent finding in connective tissue disease and can cause severe disability, there are no treatment protocols at this time. The simultaneous use of IV MPS and oral methotrexate allows for a faster control of the disease, improvement in muscular force, reduction of erythema and regression of the calcinosis without important collateral effects.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Nephrotic Syndrome II : Assessment and Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome I : Introduction